Henry Schein Inc

Noticias y eventos de Henry Schein Inc (HSIC)

$86.380

-0.605 (-0.70%)Al cierre

Noticias de HSIC

Eventos de HSIC

10/8 07:30

Henry Schein Appoints Emmanuel Caprais as CFO

Henry Schein (HSIC) announced that Emmanuel Caprais, former Senior Vice President and Chief Financial Officer of ITT, (ITT), has been named the Company's Senior Vice President and Chief Financial Officer effective November 4, 2026. Caprais will join the Henry Schein Leadership Team and report to Frederick Lowery, Chief Executive Officer of Henry Schein. After 18 years with the Company, Ronald South, Senior Vice President, Chief Financial Officer, will transition into a senior advisory role, effective November 4, 2026.

9/8 08:30

Applied BioCode Signs Distribution Agreement with Henry Schein

Applied BioCode announced a distribution agreement with Henry Schein to expand the availability of its BioCode MDx-3000 System and comprehensive molecular diagnostics menu. The BioCode MDx-3000 is an automated, high-throughput multiplex molecular diagnostic platform designed to support high-complexity clinical laboratories. Its testing menu includes upper respiratory and gastrointestinal infection panels, with a customizable menu option, enabling laboratories to deliver accurate, cost-effective, and efficient molecular diagnostic testing. Through this agreement, Henry Schein will distribute the MDx-3000 System and its associated assays to hospitals, health systems, and reference laboratories nationwide, helping broaden access to advanced molecular diagnostic capabilities.

8/4 06:30

2026 EPS Consensus at $5.34, Revenue Growth View Raised to 4.5%-5.5%

2026 EPS consensus $5.34. Raises 2026 revenue growth view to 4.5%-5.5% from 3%-5%, consensus $13.75B. 2025 revenue was $13.18B.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar